definition of community-acquired infections. Ann Intern Med 2002;137:791-797. 9. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spec- trum beta-lactamase production in Klebsiella pneumoniae iso- lates causing bacteremia. Clin Infect Dis 2000;30:473-478. 10. Kang CI, Kim SH, Kim DM, et al. Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneu- moniae. Microb Drug Resist 2004;10:71-76. 11. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lacta- mase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;33:1288-1294. 12. Kang CI, Kim SH, Park WB, et al. Clinical epidemiology of ciprofloxacin resistance and its relationship to broad-spectrum cephalosporin resistance in bloodstream infections caused by Enterobacter species. Infect Control Hosp Epidemiol 2005;26:88-92. 13. Kim JY, Park YJ, Kim SI, Kang MW, Lee SO, Lee KY. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital. J Antimicrob Chemother 2004;54:1144-1147. 14. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associ- ated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2009;30:746-752. 15. Tacconelli E, De Angelis G, Cataldo MA, et al. Antibiotic usage Sohn KM, et al. Ciprofloxacin-resistant P. mirabilis bacteremia 93 and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 2009;53:4264-4269. 16. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug- resistant Pseudomonas aeruginosa and Acinetobacter bauman- nii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71-93. 17. Jacoby G, Cattoir V, Hooper D, et al. qnr Gene nomenclature. Antimicrob Agents Chemother 2008;52:2297-2299. 18. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resis- tance from a transferable plasmid. Lancet 1998;351:797-799. 19. Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. Prevalence of plasmid-mediated quinolone resistance determi- nants over a 9-year period. Antimicrob Agents Chemother 2009;53:639-645. 20. Wu JJ, Ko WC, Wu HM, Yan JJ. Prevalence of Qnr determinants among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae in a Taiwanese hospital, 1999-2005. J Antimicrob Chemother 2008;61:1234-1239. 21. Wang M, Guo Q, Xu X, et al. New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother 2009;53:1892-1897. 22. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for com- munity-acquired urinary tract infection due to quinolone-resis- tant E. coli. Infection 2008;36:41-45. 23. Levin PD, Fowler RA, Guest C, Sibbald WJ, Kiss A, Simor AE. Risk factors associated with resistance to ciprofloxacin in clinical bacterial isolates from intensive care unit patients. Infect Control Hosp Epidemiol 2007;28:331-336.